Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. Hormone. Institut Paoli-Calmettes, Marseille, France

Survival: 58.9 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: France
City/State/Province: Marseille
Hospital: Institut Paoli-Calmettes
Journal: Link
Date: 2/2013

This phase 3 study involved non-castrate (hormone-sensitive) prostate cancer patients who were divided into two separate treatment groups. Group A consisted of 192 men with a median age of 63 years. Group B had 193 men with a median age of 64 years.

Patients in group A were treated with androgen-deprivation therapy (hormone therapy) and the chemotherapy agent docetaxel.

Patients in group B were treated with androgen-deprivation therapy (hormone therapy) alone.

There were four treatment-related deaths in group A. Causes of death included neutropenia and infection. Grade 3-4 fatigue and erectile dysfunction were also reported.

The most severe toxicities were of grade 4 and included grade 3-4 erectile dysfunction and decreased libido.

The median overall survival for groups A and B was 58.9 and 54.2 months, respectively.

This study was partially supported by Sanofi-Aventis, Amgen, and AstaZeneca.

Correspondence: Dr. Gwenaelle Gravis; email:

E-mail to a Friend Email Physician More Information